

1 **Title page**

2 **Selection of Human Single Domain Antibodies (sdAb) Against Thymidine Kinase**
3 **1 and Their Incorporation Into sdAb-Fc Antibody Constructs For Potential Use In**
4 **Cancer Therapy.**

5 Edwin J. Velazquez¹, Jordan D. Cress¹, Tyler B. Humpherys¹, Toni O. Mortimer¹, David
6 M. Bellini¹, Jonathan R Skidmore¹, Kathryn R. Smith¹, Richard A. Robison¹, Scott K.
7 Weber¹ and Kim L. O'Neill¹.

8 ¹ Department of Microbiology and Molecular Biology, Brigham Young University, Provo,
9 UT, USA

10 Correspondence: Kim L. O'Neill email: kim_oneill@byu.edu

11 LSB 4007, Department of Microbiology and Molecular Biology, Brigham Young
12 University, Provo, UT, USA, 84602

13 Phone: 1+ 801-422-2449

14

15 Short Title: Human Nanobodies against TK1 and Potential use for Cancer Treatment

16

17

18

19 **Abstract**

20 Thymidine Kinase 1 (TK1) is primarily known as a cancer biomarker with good
21 prognostic capabilities for liquid and solid malignancies. However, recent studies
22 targeting TK1 at protein and mRNA levels have shown that TK1 may be useful as a
23 tumor target. In order to examine the use of TK1 as a tumor target, it is necessary to
24 develop therapeutics specific for TK1. Single domain antibodies (sdAbs), represent an
25 exciting approach for the development of immunotherapeutics due to their cost-effective
26 production and higher tumor penetration than conventional antibodies. In this study, we
27 isolated sdAb fragments specific to human TK1 from a human sdAb library. A total of
28 400 sdAbs were screened through 5 rounds of selection by monoclonal phage ELISA.
29 The most sensitive sdAb fragments were selected as candidates for preclinical testing.
30 The sdAb fragments showed specificity for human TK1 in phage ELISA, Western blot
31 analysis and had a limit of detection of 3.9 ng/ml for 4-H-TK1_A1 and 1.9 ng/ml for 4-H-
32 TK1_D1. The antibody fragments were successfully expressed and used for detection
33 of membrane associated TK1 (mTK1) through flow cytometry on cancer cells [lung
34 (~95%), colon (~87%), breast (~53%)] and healthy human mono nuclear cells (MNC).
35 The most sensitive antibody fragments, 4-H-TK1_A1 and 4-H-TK1_D1 were fused to an
36 engineered IgG1 Fc fragment. When added to cancer cells expressing mTK1 co-
37 cultured with human MNC, the anti-TK1-sdAb-IgG1_A1 and D1 were able to elicit a
38 significant antibody-dependent cell-mediated cytotoxicity (ADCC) response by human
39 MNCs against lung cancer cells compared to isotype controls ($P<0.0267$ and $P<0.0265$,
40 respectively). To our knowledge this is the first time that the isolation and evaluation of
41 human anti TK1 single domain antibodies using phage display technology has been

42 reported. The antibody fragments isolated here may represent a valuable resource for
43 the detection and the targeting of TK1 in tumor cells.

44 **Keywords:** Thymidine Kinase 1, tumor biomarker, single domain antibodies, phage
45 display, antibody-based therapies, cancer immunotherapy.

46

47

48

49

50

51

52

53

54

55

56

57

58

59 **Introduction**

60

61 Efficient DNA repair and synthesis requires a balanced supply of nucleotides and
62 coordination of the metabolic pathways utilized for their production [1]. In order to
63 sustain proliferation, malignant cells have significant alterations in the activity levels of
64 several of their nucleotide synthesis enzymes [2-4]. These alterations, particularly in the
65 pyrimidine salvage pathway, can lead to an imbalance in the cell's nucleotide pools
66 which could lead to error prone DNA replication and genome instability, a hallmark of
67 cancer [5-7]. Thymidine Kinase 1 (TK1) is a pyrimidine salvage pathway enzyme that
68 catalyzes the phosphorylation of thymidine to thymidine monophosphate [8]. In healthy
69 cells, TK1 is only elevated during the S phase, but low or absent during other cell cycle
70 stages [9-10]. However, in malignant cells TK1 expression levels are upregulated and
71 the enzyme seems to lose its normal cell cycle regulation control elements [11]. As
72 cancer progresses, TK1 activity levels increase in tissues and in serum proportionally to
73 tumor size and stage of disease [12-13]. During the last 3 decades scientific evidence
74 has shown that TK1 levels in the serum of cancer patients can be used as a biomarker
75 for early cancer detection [14-16]. As TK1 levels in serum are correlated with tumor
76 progression, patient response and cancer recurrence, TK1 has also been proposed as a
77 suitable tumor biomarker for the continued monitoring of patients [17-20].

78

79 Although the usefulness of TK1 as a tumor biomarker has been the main focus of many
80 studies, in recent years the interest in using TK1 as a tumor target for multiple cancers
81 has gradually increased [21]. In a study conducted by Malvi et al., the silencing of TK1

82 in lung adenocarcinoma (LUAD) cell lines inhibited the cell growth, migration and
83 invasion capacities of LUAD cells both in vitro and in vivo [22]. Similarly, another study
84 showed that targeting of TK1 through genetic knockdown significantly reduced cell
85 proliferation of pancreatic ductal adenocarcinoma (PDAC) cells [23]. In addition, it has
86 been reported, that some forms of TK1 seem to be able to associate to the cell
87 membrane of several cancer cell types, including leukemia, breast, lung and colon
88 tumor cells possibly through protein-protein interaction or transitory membrane
89 localization through exosomes [24-26]. Moreover, early experimental data has shown
90 that membrane associated TK1 (mTK1) in lung, colon and breast cancer cells could be
91 targeted using monoclonal antibodies. However, the study was limited in some extent
92 because the antibodies used were produced in mice and humanized antibodies are still
93 required to better evaluate potential therapeutic use in humans [27]. This evidence
94 together suggests that the targeting of TK1 both inside the cell and its mTK1 form could
95 be a possible approach for the development of novel cancer therapies. Therefore, the
96 generation of therapeutics specific for TK1 could enable us to explore the potential of
97 TK1 as a tumor target.

98
99 Monoclonal antibodies (mAbs) are suitable candidates for the development of cancer
100 therapies due to their high specificity and affinity for their molecule targets [28]. The
101 majority of current therapeutic antibodies have been produced with hybridoma
102 technology or in transgenic mice, these approaches require the use of special animals,
103 time consuming protocols and humanization or reformatting through complicated
104 techniques such as CDR engraftment before any therapeutic use is possible [29, 30].

105 Recently, phage display technology has been incorporated in the production pipeline of
106 therapeutic antibodies by many pharmaceutical companies [31, 32]. This technology
107 offers the possibility to explore vast human antibody libraries in a relatively short period
108 of time compared to hybridoma technology and does not require animals and can
109 isolate antibodies against low immunogenic antigens [33]. In addition, the antibody
110 fragments can be isolated in convenient formats that facilitate further modifications for
111 therapeutic applications [34, 35]. The use of phage display technology to obtain single
112 domain antibody fragments (sdAbs), also called nanobodies, against TK1 is a
113 convenient and appealing approach to isolate and develop biopharmaceuticals specific
114 for the targeting of TK1. In this study we isolated human antibody fragments against the
115 tumor proliferation biomarker TK1 from a sdAb library. The antibody fragments were
116 evaluated for their capacity to bind and detect TK1 in monoclonal phage ELISA,
117 Western blot and flow cytometry. The antibody fragments were then incorporated into
118 engineered IgG1 constructs and tested for their capacity to target TK1 in malignant cells
119 and elicit an ADCC response from human MNCS against cancer cells. We hypothesize
120 that engineered single domain antibodies (sdAb) specific for TK1 can efficiently target
121 TK1 high-level expressing tumor cells. Thus, the use of human sdAb molecules
122 targeting TK1 may enable us to better explore the potential of TK1 as a tumor target in
123 proliferating malignant cells.

124

125

126

127

128 **Materials and methods**

129

130 ***Isolation of anti-TK1 sdAb fragments through phage display***

131 A phage display library of human single domain antibodies developed by Dr. Daniel
132 Christ at the MRC laboratory of molecular biology was used to select high affinity anti-
133 TK1 sdAbs (Source Bioscience, Cambridge, U.K) as previously described [36]. The full
134 repertoire of sdAbs was contained within a single human VH framework (V3-23/D47)
135 fused to the gene III protein of the M13 filamentous phage. The sdAb library was
136 constructed into the pR2 (MYC VSV-G tag) plasmid and had a diversity of 3×10^9
137 fragments. Each sdAb fragment contained three diversified complementary regions
138 (CDR1, CDR2 and CDR3). Ubiquitin and Galactosidase sub libraries were also included
139 as positive controls and run previously according to the manufacturer instructions to test
140 the viability of the components of the library and verify the selection process and testing
141 of the sdAbs were performed properly.

142

143 To initially amplify the full repertoire of sdAbs, one aliquot of the library was grown in
144 500 mL of 2xTY media supplemented with 4% glucose and 100ug/ml of ampicillin until
145 the culture reached an OD_{600} of 0.5. An amount of 1×10^{12} KM13 helper phages were
146 added per each 250 ml of culture, and the culture was incubated for 1 hr. at 37 °C
147 without agitation. After infection, the media was replaced with 2xTY media containing
148 0.1 % glucose, 100 µg/ml of ampicillin and 75 µg/ml of kanamycin and the library was
149 grown for 24 hr. at 25 °C on a shaker at 250 rpm. The phages displaying the sdAb
150 fragments were then purified using polyethylene glycol 6000 (PEG) solution (Millipore

151 SIGMA, St Louis, MO, USA). The purified phages were then quantified infecting TG1
152 bacteria with serial dilutions of the phage and plating the infected TG1 on TYE amp
153 plates. Full-length human recombinant TK1 (>80% pure) produced in *E coli* (Genscript,
154 Piscataway, NJ) was diluted in phosphate buffered saline (PBS) buffer at a 0.05 mg/ml
155 concentration. TK1 was then immobilized on Maxisorp plates (ThermoFisher scientific,
156 Waltham, MA), by coating four wells with 100 ul of TK1 solution and incubating them at
157 4 °C overnight. After coating the plates overnight, the plates were blocked with 5% milk
158 PBS buffer (MPBS) for 45 min at room temperature on a shaker and 15 minutes at 37
159 °C. The plates were then washed 3 times with PBS. Approximately 5×10^{10} phages
160 displaying the full repertoire of sdAbs, were applied to each well that was coated with
161 TK1. Phages were allowed to bind for 1 hr at room temperature with moderate shaking.
162 After incubation, the wells were washed 15-20 times with PBS-T buffer (0.1% Tween)
163 and 2 times with PBS buffer. The phage-sdAbs that remained attached were then eluted
164 adding 100 μ L of a 0.1 mg/mL trypsin-TBSC buffer solution (Millipore SIGMA, St Louis,
165 MO, USA) and incubated 1 hr at room temperature with moderate shaking. The eluted
166 phages were then recovered and used to infect a 30 mL TG1 bacteria culture at 0.5
167 OD₆₀₀. The infected culture was then incubated for 1 hr at 37 °C without shaking. After
168 infection, the TG1 bacteria was harvested and resuspended in 1 mL of 2xTY media.
169 The cells were then plated on TYE, 4% glucose plates with ampicillin (100 μ g/ml). The
170 next day, colonies were scraped off and grown in 500 mL of 2xTY until the cultures
171 reached at 0.5 OD₆₀₀. The cultures were then infected with 1×10^{12} KM13 phages and
172 grown at 25 °C for 24 hr on a shaker at 250 rpm. After incubating for 24 hr, the phage-
173 antibody sub library was purified using PEG 6000 and the phage titter was determined

174 for both the eluted phages and the purified phages. This process of selection was
175 repeated 5 times. To eliminate antibodies that could possibly bind to 6xHis-tag in TK1,
176 the last two rounds of selection were done using TK1 produced in HEK 293expi cells
177 without 6xHis-tag (Origene, Rockville, Maryland, USA).

178

179 ***Polyclonal and Monoclonal Phage ELISA***

180 To monitor the increase in the overall number of TK1 binders between rounds of
181 selection the isolated phages from each round of selection were screened through
182 polyclonal phage ELISA. For polyclonal phage ELISA 96-well Costar plates (Corning,
183 NY, USA) were coated with 100 μ l of serial dilutions of TK1 (0.05 mg/ml-0.0004 mg/ml)
184 overnight at 4°C with gentle agitation. After coating the wells, plates were washed 3
185 times with PBS buffer and blocked with 240 μ l of MPBS for 45 minutes at room
186 temperature and 15 minutes at 37°C. Wells were washed 3 times with PBS and purified
187 phages diluted in MPBS (1:1 ratio) were added into each well. The plates were
188 incubated for 1 hr at room temperature with gentle agitation. After incubating the plates
189 were washed with PBS-T five times and 100 μ l of Horse Radish Peroxidase (HRP)
190 conjugated anti-M13 antibody solution (1:2,000 dilution in MPBS) were added into each
191 well. Following addition of the HRP conjugated antibody, 100 μ l of Tetramethyl
192 Benzidine (TMB) substrate (ThermoFisher scientific, Waltham, MA, USA) was added
193 into each well and color was allowed to develop 10-30 min. The reaction was stopped
194 with 50 μ l of 1M sulfuric acid, and the absorbance values were measured using a
195 Synergy HT Microplate Reader (Bio-Tek Winooski, VT) at 450 nm and 650 nm.

196

197 Eighty individual clones were tested using monoclonal phage ELISA every round of
198 selection (biopans). After each biopan and before scraping off the colonies, eighty
199 clones were picked and grown overnight at 37°C in 200 µl of 2XTY media supplemented
200 with 4% glucose and ampicillin (100 µl/ml). Culture dilutions (1:100) from the overnight
201 cultures were made by diluting 5 µl of the overnight culture in 200 µl of 2XTY 4%
202 glucose and ampicillin and grown at 37°C for three hr. After reaching a 0.5 OD₆₀₀, 50 µl
203 of 2XTY containing 4 x 10⁸ KM13 helper phages were added into each well to produce
204 phage-sdAb fragments. The infected cultures were incubated at 37°C for one hr without
205 shaking and the media was changed with 200 µl of 2XTY with 0.1% glucose, ampicillin
206 (100 µg/ml), and kanamycin (75 µg/ml). Cultures were grown at 25°C for 24 hr at 250
207 rpm. After 24 hr the plates were centrifuged at 3200 xg for 10 minutes and the
208 supernatants were recovered from each well and mixed with MPBS in 1:1 ratio. To test
209 each clone for its capacity to bind TK1 96 well plates were coated with 100 µl of a 0.01
210 mg/ml of TK1 per well as previously described. The same protocol described for
211 polyclonal phage ELISA was used to carry out the monoclonal phage ELISA.

212

213 ***Detection of phage-sdAbs by dot blot***

214 Dot blot was used to confirm the expression of sdAb fragments in TG1 supernatant.
215 After recovering supernatants containing phage-sdAb fragments, 2-3 µl of the phages
216 were immobilized on a (nitrocellulose membrane BIO-RAD, Hercules, CA). The
217 membrane was then blocked with 5% MPBS for 1 hr at room temperature on a shaker.
218 The membrane was then incubated with a 1:20,000 anti-VSV-G-HRP antibody solution
219 at 4 °C overnight with moderate shaking. The next day, the membrane was washed 3

220 times with PBS-T 5 min each wash. After the membranes were washed 2 mL of
221 enhanced chemiluminescence substrate (Advansta Corporation, San Jose, CA) was
222 added to the membrane until the membrane was completely covered. The membranes
223 were incubated for 2 minutes and the excess of reagent was poured off. Membranes
224 were covered in plastic wrap and light sensitive films were placed on the membranes at
225 different exposure times and revealed using an imaging developer.

226

227 ***Sensitivity of TK1 specific antibody fragments***

228 Sensitivity of TK1 sdAbs was determined using dose-response curves and monoclonal
229 phage ELISA. Briefly, Costar 96-well plates (Corning) were coated with serial dilutions
230 of TK1 (ranging from 23,600 ng/ml-23 ng/ml for E-TK1 and 500 ng/ml-1.9 ng/ml for H-
231 TK1) overnight at 4°C overnight. The next day, plates were blocked with 2400 µl of
232 MPBS/well for 45 minutes at room temperature and 15 minutes at 37°C. After blocking,
233 the wells were washed three times with PBS and 100 µl of a 1:1 dilution of phage
234 supernatant in MPBS was added into each well. Subsequent steps were carried out as
235 previously described to develop the ELISA. The curves were then analyzed using a
236 four-point parameter logistic curve and the limit of detection of each sdAb fragment was
237 determined. The sensitivity of the clones was then compared. In the case of soluble
238 fragments that were expressed without fusion to the PIII protein of the phage, the same
239 ELISA protocol was used except detection antibodies changed to anti-His-HRP
240 (Biolegend, San Diego, CA) and anti-VSV-G-HRP (Bethyl, Montgomery, TX).

241

242 ***Validation with a TK1 siRNA and non-specific binding controls***

243 In order to confirm specific binding to TK1, individual clones were screened against cell
244 lysate from a siRNA TK1 knockout and compared to wild type cell lysate. TK1 knock
245 down cell lysate was prepared as previously described [25]. TK1 produced in bacterial,
246 yeast, and mammalian expression systems were used as positive controls and
247 uncoated wells were used as negative controls. The protocol for a monoclonal phage
248 ELISA was performed as described above.

249

250 ***Sequencing Analysis of sdAb fragments***

251 Plasmid was isolated from the clones that showed the highest affinity for TK1 using the
252 PureYield Plasmid Miniprep system (Promega). Samples were prepared for sequencing
253 using the primer (5' CCCTCATAGTTAGCGTAACGA 3') and the universal M13 reverse
254 primer (5' CAGGAAACAGCTATGAC 3'). Sequencing data was analyzed using Genious
255 prime software [37].

256

257 ***Anti-TK1-sdAbs protein modeling and docking analysis of sdAb-TK1 complexes***

258 The structures of the anti-TK1-sdAb fragments were analyzed using the GalaxyWEB
259 TMB web server. The most stable structures of each anti-TK1 sdAb fragment were
260 analyzed using the Visual Molecular Dynamics (VMD) software developed by the
261 computer science, and biophysics at the university of Illinois [38]. The CDR regions
262 were mapped by analyzing the deduced amino acid sequences of each anti-TK1-sdAb
263 fragment in the IgG Blast tool from NCBI. The sequences of the anti-TK1-sdAb
264 fragments were aligned using Genious prime software. In silico analysis of the
265 interaction between the anti-TK1-sdAb fragments and the crystal structure of TK1 was

266 performed using the high ambiguity driven protein-protein docking (HADDOCK) web
267 server [39]. Visualization of the anti-TK1-sdAb-TK1 complexes was also performed with
268 VDM software.

269

270 ***PCR amplification and cloning into pET-scFv-T***

271 Sequences of the sdAb fragments were amplified from the phagemid plasmids
272 corresponding to the isolated positive clones in phage ELISA. The sequences were
273 amplified using primers containing the NcoI restriction site (5'
274 GAACATATGATGAAAAATTATTA 3') and the NotI restriction site (5'
275 GAAGGATCCTGCGGCCCCCTTTC 3'). PCR products were run in a 1% agarose gel
276 and desired sequences were extracted using the Zymoclean DNA Gel Recovery Kit
277 (Zymo research, Irvine, CA, USA). Following gel recovery, sdAb sequences were
278 digested using NcoI and NotI restriction enzymes (New England Biolabs, Ipswich, MA,
279 USA). Digested sequences were then ligated into the pET-scFv-T backbone (Addgene,
280 Watertown, MA). Ligation was carried out using the Quick Ligation kit (New England
281 Biolabs, MA). The ligated plasmids were then cloned into Dha5 competent cells.
282 Colonies from transformation product were grown for 16- 20 hr and plasmid were
283 isolated and analyzed by restriction enzyme analysis to verify the presence of the insert.
284 Positive clones were then sequenced.

285

286 ***Expression of antibody fragments in Rosseta 2(DE3) pLysS E. coli cells and His-*** 287 ***tag purification***

288 The pET-TK1-sdAb-6xHis constructs were cloned into Rosseta blue(DE3) pLysS *E. coli*
289 cells (Millipore SIGMA, St Louis, MO). Individual colonies were selected and grown in a
290 culture overnight at 37°C. The overnight culture was then scaled up and grown until the
291 OD reached 0.6. Expression of the sdAb fragments was induced by addition of 0.4 mM
292 Isopropyl β -d-1-thiogalactopyranoside (IPTG). After IPTG induction, the cultures were
293 grown for 24 hr at 28°C. The Rosseta blue(DE3) pLysS *E. coli* cells were pelleted and
294 the supernatant was saved for later purification. The cells were subjected to osmotic
295 shock by resuspending cells in TES buffer (20 mM Tris-HCl pH 7.6, 5 mM EDTA, and
296 20% sucrose). After a one hr incubation on ice, the sample was centrifuged at 14,000
297 xg for 20 minutes. The pellets were resuspended in ddH₂O and incubated on ice for 30
298 minutes. Centrifugation was repeated and the supernatant was preserved. The cell
299 pellet was lysated using 10X bug buster reagent (Millipore SIGMA, St Louis, MO)
300 diluted in 20 mM Tris-HCl (pH 7.8) buffer containing 15 mM NaCl, 5 mM MgCl₂, DNase
301 (25 U/ml) and protease inhibitors. Cells were lysated for 20 min on shaker with
302 moderate agitation. After incubating in cell lysis, the lysated cells were spun down
303 16,000 g for 20 min and the supernatant was recovered. Supernatants were mixed
304 with equilibrated Ni-NTA agarose beads (Qiagen, Hilden, Germany) for 3 hr at 4 °C.
305 After incubating the NI-NTA beads were washed twice with cell lysis buffer and
306 placed into 5 ml polypropylene columns. The Ni-NTA beads were then washed with
307 50 ml of wash buffer and then the His-tagged proteins were eluted with elution
308 buffer in 0.3 ml fractions. The fractions were analyzed by SDS-PAGE and Western
309 blot to detect the purified anti-TK1 sdAb fragments and estimate their purity.
310

311

312

313 ***Western blot with purified anti TK1-sdAb fragments***

314 The purified fragments were tested for their capacity to bind to purified TK1 and TK1 in
315 cell lysate through Western blot. Recombinant human TK1 produced in bacteria and
316 Expi293F cells were used along with cell lysate from A549 lung cancer cell lysates,
317 including a siRNA TK1 knockdown cell lysate. Briefly, 0.5 µg of TK1 or 20 µg of cell
318 lysate were mixed with 6x Laemmli buffer (Millipore SIGMA, St Louis, MO). The protein
319 samples were then heated at 100 °C for 5 min and loaded into a 12 % SDS-PAGE
320 electrophoresis. The proteins from the gel were then transferred to nitrocellulose
321 membranes (Bio-Rad, Hercules, CA, USA). After blocking with 5 % milk in MPBS buffer
322 for 1 hr at room temperature the blocking solution was poured out and anti-TK1 sdAb
323 fragment solution (1 ug/ml-2 ug/ml) was added. Membranes were incubated at 4 °C
324 overnight. After overnight incubation membranes were washed 3 times with PBS-T
325 buffer. The bound proteins were detected using a 1:20,000 solution of an anti-VSV-G-
326 HRP and anti-His-HRP antibody (Bethyl, Montgomery, TX, USA). The proteins were
327 then detected through the peroxidase reaction using enhanced chemiluminescence
328 (ECL) (Advansta Corporation, San Jose, CA). Films were exposed for different amounts
329 of time depending on the antibody being tested, times ranged from 30 seconds to 5 min.
330 The films were scanned, and the images were analyzed using the software ImageJ from
331 NIH.

332

333

334

335 ***Cell lines and Isolation of human MNCs***

336 The NCI-H460 (ATCCHTB-177TM), A549 (ATCC[®] CCL-185), HCC1806 (ATCC[®] CRL-
337 2335TM) and HT-29 (ATCC[®] HTB-38TM) cell lines were obtained from the American Type
338 Culture Collection (ATCC, Manassas, VA, USA) and maintained according to ATCC
339 recommendations. A549, NCI-H460, HCC1806 and HT-29 were cultured in RPMI-1640
340 media (ThermoFisher scientific, Waltham, MA) supplemented with 10% fetal bovine
341 serum (FBS) and 2mM L-Glutamine. All cell lines were grown in an incubator at 37 °C
342 and 5% CO₂. All cell lines used were tested for TK1 surface expression with flow
343 cytometry with a commercial antibody Abcam91651 (Abcam, Cambridge, UK) to confirm
344 the presence of TK1 on the cell membrane. MNC were isolated with lymphocyte
345 separation media (Corning, NY) following manufacturer instructions, red blood cells
346 were depleted with red blood cell lysis buffer (Biolegend, San Diego, CA) and the MNC
347 were resuspended in LGM-3 (Lonza, Basel, Switzerland). Blood withdrawal was done
348 under the institutional review board approval.

349

350 ***Flow cytometry***

351 The purified phage-sdAb fragments, anti-TK1 sdAb fragments, and anti-TK1-sdAb-IgG1
352 fusions were all tested for their capacity to detect mTK1 in the cancer cell lines NCI-
353 H460, HCC1806, HT-29, and normal MNCs. For this analysis 1X10⁶ cells per sample
354 were analyzed. Cells were washed twice with PBS and resuspended in 200 µl of cell

355 staining buffer. After resuspending, the cells were stained using PEG purified phage-
356 TK1-sdAb fragments (100 μ l), purified sdAb fragments (5-10 μ g), or purified sdAb-IgG1
357 antibodies for 40 min. The cells were then washed 3 times with 200 μ l of cell staining
358 buffer and stained for 30 min with anti-his-APC or anti-VSV-G-FITC antibodies in the
359 case of purified phage-sdAb fragments, anti-M13-FITC secondary antibody. To detect
360 binding of sdAb-IgG1 antibody fusions anti-Human IgG-FITC antibody (Abcam,
361 Cambridge, UK) was used. After incubation with secondary antibody, the cells were
362 washed 3 times with 200 μ l of cell staining buffer. Before analysis samples were stained
363 with 10 μ g/ml PI solution and the samples were analyzed in a Cytoflex flow cytometer
364 machine (Beckman Coulter, Brea, CA). The FCS files were analyzed using the FlowJo
365 software (FlowJo, Inc., Ashland, OR).

366

367 ***Incorporation of TK1-sdAb fragments into pFUSE-IgG1 construct and antibody***
368 ***expression in CHO cells***

369 The DNA sequences of the top two anti-TK1 sdAbs were cloned between the NcoI and
370 EcoRI restriction sites of the pFUSE-hIgG1e5-Fc2 vector (InvivoGen, San Diego, CA).
371 This vector is designed for the production of human recombinant antibodies in
372 mammalian cells and contains a human IgG1 heavy chain mutated at the
373 S239D/A330L/I332E sites which confers an increased binding to Fc γ IIIa receptors in
374 macrophages (MO) and natural killer cells (NK). Thus, the recombinant antibodies fused
375 to this engineered IgG1, can elicit an enhanced antibody-dependent cell-mediated
376 cytotoxicity (ADCC). The primers used for the amplification of the sdAb fragments for
377 this construct were primer Fw- 5' GAAGAATTCGATGGCCGAGGTGCAG 3' and primer

378 Rv- 5' GGCCCATGG CGCTCGAGACGGTGAC 3'. The two TK1-scFv-hlgG1 DNA
379 constructs were introduced into CHO.K1 cells (ATCC, Manassas, VA, USA) by
380 lipofection using the lipofectamine LTX reagent (ThermoFisher scientific, Waltham, MA).
381 After 48hr the media was changed and Zeocin selection antibiotic (InvivoGen, San
382 Diego, CA, USA) was added at a concentration of 100 µg/ml. After 10 days in selection
383 the cells were expanded. The media was then changed with ProCHO™ AT (Lonza,
384 Basilea, Switzerland) and the recombinant antibodies were allowed to be produced for
385 48-96 hr or until cell viability was about 50 %. The media was collected and cleared
386 from cells by centrifugation. The anti-TK1-scFv-hlgG1 antibodies were then purified
387 from cleared media using protein A purification columns (ThermoFisher scientific,
388 Waltham, MA). Characterization of the purified recombinant antibodies was carried out
389 with Western blot and flow cytometry as described above.

390

391 ***In vitro testing of anti-TK1-sdAb-IgG1 Antibodies through ADCC***

392 The capacity of the TK1-sdAb-IgG1 antibodies to target mTK1 on cancer cells and elicit
393 an ADCC response was evaluated *in vitro*. For this experiments NCI-H460 cells, which
394 expressed high levels of mTK1, were engineered to express cytosolic GFP. The cells
395 were then co-cultured with human MNC and anti TK1-sdAb-IgG1 antibodies were added
396 in various concentrations. Cell death was then measured using a real time cell imaging
397 system. The experiments were conducted as follows. One day before treating the cells
398 with antibodies and controls 5000 NCI-H460 GFP+ cells were seeded per well in a 96-
399 well tissue culture plate (MIDSCI, St. Louis, MO), placed inside an ImageXpress® Pico
400 system. The GFP+ cells were counted every hr for the next 8-12 hr. After initial growth

401 human MNCs were added at two different ratios, 5:1 and 10:1. The cells were co-
402 cultured using LGM-3 media to sustain MNC and antibodies were added at various
403 concentrations (20, 10, 5, 2.5 ug per well) . And optimized 5:1 effector:target ratio and a
404 concentration of 10 µg of antibody/ml were used for experiments. The cells were
405 monitored for 72-96 hr under environmental controlled conditions. The number of cells
406 from each treatment including controls were analyzed and compared through time.
407 Each experiment was run twice and each well receiving a treatment was run in
408 duplicate.

409

410 ***Statistical analysis***

411

412 Statistical analyses were performed using the GraphPad Prism software (GraphPad,
413 San Diego, CA). ELISA data from dilution curves was log-transformed and analyzed
414 with a 4-parameter non-linear regression analysis with a 95% confidence interval (CI).
415 To compare the different treatments of the ADCC experiments, the data was normalized
416 in reference to the moment MNC and antibodies were added and analyzed using a two-
417 way ANOVA with repeated measure analysis. Analysis of multiple comparisons was
418 performed comparing the mean of each treatment with every other treatment mean in
419 each time point and over the total course of time. One-way ANOVA were performed to
420 compare normalized GFP+ cell counts at specific time points.

421

422

423

424 **Results**

425

426 ***Antigen validation***

427 Each of the antigens used for the selection of the sdAbs were validated before the
428 biopanning process. Recombinant human TK1 was produced in *E. coli* (E-TK1) and was
429 used during early rounds of selection at high concentrations while TK1 produced in
430 human Expi293F cells (H-TK1) was used for the last rounds of selection at lower
431 concentrations. This is because H-TK1 that produced in human cells was properly
432 folded. Both antigens were validated through Western blot using the KO validated anti-
433 TK1 antibody ab91651(Abcam, Cambridge, UK). Both E-TK1 and H-TK1 purified
434 fractions were positive for TK1 and showed bands respective to the monomer and dimer
435 of TK1. The pureness of the antigens showed to be higher than 80% according to SDS
436 page and Coomassie blue staining (Fig. 1A, right).

437

438 **Fig.1.** A) Antigen validation, the pureness and integrity of human recombinant TK1
439 produced in *E. coli* cells and Expi293F cells was assessed in SDS-PAGE and validated
440 through Western blot using the anti-TK1 antibody ab91651. B) Enrichment of TK1
441 binders through 5 rounds of selection. The number of binders was estimated based on
442 titrations of eluted phages used to infect TG1 bacteria. C) A representative image of a
443 viral titration to determine the number of eluted phages. TG1 bacteria was infected with
444 serial dilutions of the eluted phages after each biopans. The infected TG1 was then
445 plated on TYE amp plates.

446

447 ***Isolation and validation of anti-TK1 sdAb fragments***

448 The isolation of anti-TK1-ssdAbs was monitored after each biopan by determining the
449 phage titer from the eluted phages. As expected, the number of eluted phages per ml
450 increased exponentially through the 5 rounds of selection (Table 1, Fig. 1B). This trend
451 could be observed by infecting TG1 bacteria with the eluted phages, plating the bacteria
452 in selective agar plates and then determining the number of CFU/ml (Fig. 1C). After 3
453 consecutive rounds of selection with recombinant human TK1 produced in *E. coli* the
454 enrichment factor of TK1 binders went from 1 to 48.9. (Table 1). Two more rounds of
455 selection were performed using recombinant H-TK1 to eliminate non-specific sdAb
456 fragments that could possibly bind to the His-tag present in E-TK1 and also to obtain
457 fragments that could bind to properly folded human TK1. We observed that the
458 enrichment factor increased in a 3-fold after 1 round of selection with H-TK1 and then
459 doubled in a subsequent round of selection using H-TK1.

460

Table I. Enrichment of anti-TK1-sdAb phages through 5 rounds of selection.

Round of selection	Input phages	eluted phages	Ration (eluted/input)	Enrichment factor
1	5.00E+12	4.12E+04	8.24E-09	1.00
2	5.00E+12	1.60E+06	3.20E-07	38.83
3	5.00E+12	2.01E+06	4.03E-07	48.91
4	5.00E+12	5.20E+06	1.04E-06	126.21
5	5.00E+12	1.13E+07	2.27E-06	275.49

461

462 After each biopan 80 individual clones were screened through monoclonal phage
463 ELISA. The purified phages after each round of selection were also monitored through
464 polyclonal phage ELISA. As expected, an exponential increase in the number of positive
465 clones after each biopan was observed. About 50 % of the clones produced a positive
466 signal by the 4th biopan and about 90% of the clones were positive in the 5th biopan
467 (Fig. 2A). A similar trend was observed in polyclonal phage ELISA where the signal
468 produced by the total purified phages after each round of selection also significantly
469 increased after the first biopan and kept increasing almost in a 2-fold between each
470 biopan from the 2nd to the 4th biopans (Fig. 2B). Although the number of positive clones
471 in monoclonal phage ELISA showed a significant increase from the 4 to the 5th biopan,
472 no significant increase in the overall signal was produced in polyclonal phage ELISA.
473 This was consistent with what was observed in the monoclonal phage ELISAs where we
474 see significant increases in the number of positive clones from the 1st through the 4th
475 biopans.

476

477 **Fig.2.** Selection and expression of anti-TK1-sdAb phages. A) Analysis of 80 clones
478 through monoclonal phage ELISA was done after each round of selection. B) Polyclonal
479 phage ELISA using the total purified phages per round of selection. In both A and B and
480 increase in the overall signal and number of positive clones increases after each round
481 of selection. C) Detection of anti-TK1-sdAb phages through dot blot using an anti-VSV-
482 G-HRP antibody. Also, verification of packaging of the library from PEG purified phages
483 after initial amplification of the sdAb library. D) Representative image of monoclonal
484 phage ELISAs through the rounds of selection.

485

486 In addition to monoclonal and polyclonal phage ELISA, we screened purified phages
487 and individual supernatants containing phages with Western blot and dot blot. Since
488 each antibody fragment that is displayed in the M13 phages has a Myc and VSV-G tags
489 we detected the production of phage-antibodies using anti-VSV-G-HRP conjugated
490 antibody. Western blot analysis of the purified phages revealed the presence of bands
491 corresponding to phage-sdAb fusions. Dot blot analysis of individual clones showed the
492 successful production of individual phage-sdAbs (Fig. 2C).

493

494 After the initial screens in monoclonal phage ELISA, 26 clones were chosen for their
495 ability to produce high signals. These included clones from the 2nd, 3rd and 4th rounds of
496 selection. Clones from the 5th round were excluded due to a decrease in the diversity of
497 sequences product of amplification of some specific phage-sdAbs with high affinity. The
498 clones were re-tested to confirm their capacity to bind TK1 and reproduce a positive
499 signal. From the 26 selected clones, 14 clones were able to reproduce a positive signal
500 after the initial screen (Fig. 3).

501

502 **Fig. 3.** Confirmation of positive clones. To verify that the positive clones found during
503 the initial screening, their capacity to reproduce a positive signal was tested. The
504 strongest positive clones were selected through the different rounds of selection.
505 Bacteria corresponding to each of these clones was streaked for second time on TYE
506 amp plates. New cultures were grown from a single colony and infected with KM13
507 helper phage to induce the production of their respective anti-TK1 phage-ssdAbs. A)

508 Positive anti-TK1 phage-ssdAbs tested in monoclonal phage ELISA. Their capacity to
509 bind TK1 and the stability of each clone was confirmed. B) Representative image
510 showing the color development generated by the positive clones and plate layout
511 indicating the position of each clone that was tested.

512

513 After confirming their binding to TK1, the positive clones were tested with dose
514 calibrations curves to see if they were able to bind TK1 proportionally to its
515 concentration and to determine their sensitivity. The 14 clones showed all sigmoidal
516 curves according to our non-linear 4-point logistic analysis. The goodness of fit test
517 showed R squares ranging between 0.9964-0.9772. The curves behaved according to
518 receptor-ligand interactions models, showing that the binding of the anti-TK1-sdAbs
519 were proportional to the concentration of TK1 in each well (Fig. 4A). This could also be
520 visually appreciated in the colorimetric reactions in the dilution curves for each clone
521 (Fig. 4B). There was not significant background signal produced by the clones in the
522 blanks.

523

524 **Fig.4.** A) Dose response curves corresponding to anti-TK1 sdAb fragments obtained
525 through various rounds of selection. The data was Log transformed and the curves were
526 analyzed using a 4-parameter non-linear regression. B) A representative image of the
527 colorimetric reaction showing that the signal of each anti-TK1 sdAb fragment is
528 proportional to the concentration of TK1 protein. Negligible or no significant signal was
529 produced in the blanks.

530

531 The clones that were the most sensitive were clones 4-H-TK1_A1 and 4-H-TK1_D1.
532 Using the phage supernatant from these clones we were able to detect TK1 protein
533 levels as low as 23 ng/ml in monoclonal phage ELISA (Fig. 5A). Further sequencing of
534 the clones revealed that the sequences between clones 4-H-TK1_A1 and 4-H-TK1_D1
535 were different.

536
537 **Fig.5.** Sensitivity and specificity of the anti-TK1-sdAb fragments. A) The 14 anti-TK1
538 sdAb fragments were tested with a minimal fixed concentration of 23ng/ml of human
539 TK1 produced in human cells (H-TK1). The sdAbs 4-H-TK1_A1 and 4-H-TK1_D1
540 produced the highest signals. B) Dilution curves with H-TK1 and the top two clones.
541 Concentrations ranged from 500 ng/ml to 3.9 ng/ml, the fragments keep their binding
542 properties after being expressed as sdAb fragments C) siRNA TK1 knock down
543 validation. TK1 was knockdown in A549 cells. The knockdown was validated using
544 commercial anti-TK1 antibody. D) Validation of the top 2 anti-TK1-ssdAbs. The binding
545 capacity of the sdAb fragments was tested against 3 different sources of human
546 recombinant TK1 and cell lysate from the cancer cell line A549 and cell lysate from
547 A549 TK1 knockdown. It can be appreciated that both fragments bind to the 3 different
548 recombinant TK1 proteins. A significant difference can be appreciated in the signal
549 coming from the normal cell lysate in comparison with the TK1 knockdown cell lysate.

550
551 Anti-TK1-sdAbs phages 4-H-TK1_A1 and 4-H-TK1_D1 shown capacity to bind H-TK1 in
552 phage ELISA. The signal was proportional to H-TK1 concentration (Fig. 5B). Validation
553 of the clones 4-H-TK1_A1 and 4-H-TK1_D1 using a siRNA TK1 knockdown and

554 different sources of recombinant human TK1 revealed that the clones were able to bind
555 to E-TK1(produced in *E. coli*), H-TK1(produced in Expi293F cells) and TK1 produced in
556 a yeast system. Moreover, the signal coming from cell lysate from A549 cells was
557 significantly higher (~10-fold) to the signal coming from the cell lysate of A549 TK1
558 knockdown for both 4-H-TK1_A1 ($P<0.0296$) and 4-H-TK1_D1 ($P<0.0129$). A TK1
559 knock down was produced as previously described for this experiment (Fig 5C and D)
560 [27].

561
562 ***Amplification of sdAB fragments, sequencing and cloning into pET-scFv-T vector***

563 The dAb fragments were amplified by PCR and ligated into the pEt-scFv-T vector
564 successfully as shown in Figure 6. The anti-TK1-sdAb vectors were sequenced, and the
565 amino acid sequences were deduced from their nucleotide sequences (Table 2).

566
567 **Fig.6.** Amplification and ligation of anti-TK1-dAb fragments into the pET-scFv-T
568 expression vector (Addgene #67843). A) a representative image of a PCR showing
569 amplification of anti-TK1 dAb fragments. B) Restriction enzyme analysis with NcoI and
570 NotI enzymes of pET-Anti-TK1-dAb constructs. C) Map of a pET-Anti-TK1-dAb
571 construct. Fragments are ligated into the pET-scFv plasmid using NcoI and NotI
572 restriction sites. D) Alignment of the 4-H-TK1_A1 and 4-H-TK1_D1 sdAb sequences
573 shows the differences of the sdAbs are in their CDRs.

574
575 Further analysis of the nucleotide sequences of the Anti-TK1 dAb fragments with the
576 IgG blast tool from NCBI revealed the specific sites for their respective CDRs. The

577 annotated sequences are found in Table 2. In addition, the alignment of the sequences
578 using genius software confirmed that the annotated CDRs were the regions with most
579 differences among the sequences while the heavy chain framework regions remained
580 conserved (See Fig. 6D). This is consistent with the original description of the library
581 which was built in a human VH framework and introduced diversity in the CDRs.

582

583 Table 2. The deduced amino acid sequences of the top two anti-TK1 sdAb fragments
584 isolated through phage display. CDRs were mapped using the IgBLAST tool. The
585 antibodies sequences were aligned and compared using Genious prime software.

Anti-TK1 dAb	FR1	CDR1	FR2	CDR2
4-H-TK1_A1	MAVQLLESGLVQPGGSLRLSCAA	SGDRFTDEN	MSWVRQAPGKGLEWVSA	IDNADGST
4-HTK1_D1	MAVQLLESGLVEPGGSLRLSCAAS	GDSFTTKN	MAWVRQAPGKGLEWVSA	ISKRSGST

Anti-TK1 dAb	FR3	CDR3	FR4
4-H-TK1_A1	YYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYC	AAGFVHAVVQKEFYSPVKF	WGQGTLVTVSSAAAG
4-HTK1_D1	YYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYC	AGLTQRHGHAALKY	WGQGTLVTVSSAAAG

586

587 ***Analysis of protein structure of Anti-TK1-sdAb fragments and modeling of sdAb-*** 588 ***TK1 complexes***

589 After submitting the corresponding amino acid sequences from the Anti-TK1 sdAb
590 fragments A1, and D1 into the GalaxyTBM server, 5 model structures were generated
591 for each fragment. The most stable structure from each anti-TK1-sdAb was then
592 visualized using the VMD software. The Anti-TK1-sdAb fragments presented a typical
593 structure of a sandwich of two antiparallel β -sheets according to previously reported

594 single domain structures [40]. Their CDRs were contained in the loops connecting their
595 antiparallel β -sheets having the CDR3 a longer loop according to the sdAb library design
596 (Fig. 7 A-B). Furthermore, analysis of the interaction between the anti-TK1_4-H-A1
597 sdAb and the 1XBT crystal structure of TK1 [41] using the high ambiguity driven protein-
598 protein docking (HADDOCK) web server revealed the interaction of the anti-TK1 sdAb
599 4-H-TK1_A1 through its CDRs with TK1. The CDRs seemed to interact with the α 1-
600 ribbon towards the N-terminus and two regions close to the β -ribbons at the c-terminus
601 of the TK1 molecule (Fig. 7C and D).

602
603 **Fig.7.** The 3D structure of the top two anti-TK1-sdAb fragments based on their deduced
604 amino acid sequences. The Anti-TK1-sdAb fragments were modeled using GalaxyWeb
605 TBM server. The most stable structures were then visualized using the VMD 1.9.3
606 software. CDRs were mapped by analyzing the anti-TK1 sdAb amino acid sequences
607 with the IgBlast tool from NCBI. A) H-4-TK1_A1 sdAb. B) H-4-TK1_D1 sdAb. C) High
608 ambiguity driven protein-protein docking analysis using the HADDOCK 2.4 webserver.
609 The most stable structures of the H-4-TK1-A1 sdAb fragment and human TK1 protein
610 monomer were analyzed to predict their protein-protein interactions. The analysis shows
611 that the most reliable TK1-sdAb fragment complex would bind through its CDRs to TK1.
612 The CDRs would interact with the α 1-ribbon towards the N-terminus and two regions
613 close to the β -ribbons towards the c-terminus of the TK1 molecule. D) Docking between
614 the Anti-TK1 sdAb H-4-TK1_A1 and the monomer of human TK1 from the 1XBT crystal
615 structure.

616

617 ***Expression and characterization of purified sdAb fragments***

618 The anti-TK1 sdAbs H-4-TK1_A1 and H-4-TK1_D1 were successfully expressed using
619 the pET-scFv-T system. The fragments were detected with anti-His-HRP and anti-VSV-
620 G-HRP antibodies in Western blot as could be observed (Fig. 8A). Moreover,
621 coomassie blue staining showed successful purification of a 12-15 kDa band which
622 matched the size of the band shown in Western blot. Purification of sdAb fragments with
623 Ni-NTA bind-His resin yields were between 1 up to 4 mg/ml of purified fragment (Fig.
624 8B). Alternatively, the fragments that are VSV-G-tagged were purified using protein A
625 columns (Fig. 8C). Although, the yields in protein A purification were lower, about 0.4
626 mg/ml (Fig. 8D).

627

628

629 **Fig.8.**Expression and purification of anti-TK1 sdAbs. A) Detection of anti-TK1 sdAb
630 fragments with anti-His-HRP antibody in Western blot and their respective SDS-PAGE
631 analysis. B) Quantification of the His-tag purified sdAb fragments with BCA assay. The
632 protein yields ranged between 1-4 mg/ml of purified sdAb. C) Western blot and SDS-
633 PAGE analysis of protein A purified anti-TK1 sdAb H-4-TK1_A1. The antibody
634 fragments can alternatively be purified with protein A purification. D) Quantification of
635 protein A purified anti-TK1 sdAb H-4-TK1_A1.

636

637 ***Western blot and soluble ELISA***

638 After being expressed as sdAb fragments without a PIII gene fusion, the purified anti-
639 TK1-sdAbs kept their binding properties to TK1 similarly to the ones observed when

640 expressed as PIII fusions displayed on filamentous phages. These were tested through
641 soluble ELISA. As shown, the anti-TK1 sdAbs bound proportionally to the concentration
642 of TK1 in the wells. Concentrations ranged between 500 ng/ml-1.9 ng/ml of H-TK1. The
643 anti-TK1-ssdAbs were able to produce signal significantly higher than the blanks at
644 concentrations 3.9 ng/ml for H-4-TK1-A1 and 1.9 ng/ml for H-4-TK1-D1(Fig. 9A)

645
646
647 **Fig.9.** Soluble ELISA and Western blot analysis. A) Purified recombinant anti-TK1
648 sdAbs kept their binding properties H-TK1 after being expressed in *E. coli* and His-tag
649 purified as observed in soluble ELISA. B) The anti-TK1 sdAbs showed binding to
650 recombinant human TK1 produced in both *E. coli* (E-TK1) and human cells (H-TK1).
651 The fragments were validated comparing their binding to TK1 in cell lysate of A549 cells
652 (100 ug) and A549 TK1 knockdown (100ug). C)Detection of TK1 in cell lysate of 4
653 different cancer cell lines and normal MNCs (20ug each). The fragments were able to
654 detect TK1 tetrameric form, controls included commercial anti-TK1 abcam91615 and
655 GAPDH. D) A representative Western blot image showing detection of TK1 in human
656 serum from a cancer patient and a healthy individual using anti-TK1_A1 and D1
657 fragments. For each cancer and healthy serum 10 ug of serum protein were loaded into
658 each lane. A difference in the signal can visually be observed being the signal in the
659 cancer serum slightly higher than the signal in normal serum

660
661 The anti-TK1-sdAbs were then tested in Western blot. As can be observed in Fig. 9B,
662 the anti-TK1-ssdAbs showed binding to recombinant human TK1 produced in *E. coli*,

663 and Expi293F cells. Moreover, the Anti-TK1 sdAb fragments showed a significantly
664 higher signal in A549 cell lysate compared to A549 TK1 siRNA knockdown, particularly
665 fragment 4-H-TK1_A1 showed specificity for TK1 (Fig. 9B).

666
667 Once we confirmed the binding of the fragments to purified recombinant TK1 and
668 validated their specificity using a TK1 siRNA knockdown we proceeded to test its
669 capacity to detect TK1 in cell lysates of different cancer cell lines, including, NCI-H460,
670 HT-29, MDA-MB-231, PC3 and human MNC. It could be observed that the anti-TK1
671 sdAbs were able to detect bands corresponding 100 kDa in all cell lysates. In the case
672 of MDA-MB-231 cells the sdAbs were also able to detect 50 kDa (Fig. 9C). This maybe
673 corresponding to the active forms of TK1 dimer and tetramer. In a separate Western
674 blot analysis, the anti-TK1-sdAbs were able to detect monomeric and dimeric forms of
675 TK1 in human serum from a stage IV lung cancer patient which produce a higher signal
676 compared to serum from a healthy patient (Fig. 9D).

677

678 ***Flow cytometry***

679 Detection of membrane expression of TK1 in NCI-H460 cells was done by staining the
680 cells with PEG purified phages from each respective clone. We observed that after
681 subtracting the background binding from the anti-M13-APC antibody there was an
682 increase in binding to the cells stained with the anti-TK1-sdAbs of 20% and 25% for H-
683 4-TK1_A1 and H-4-TK1_D1 sdAbs respectively (Fig. 10A). Therefore, the anti TK1
684 sdAbs showed capacity to detect membrane expression of TK1 on NCI-H460 cells. NCI-

685 H460 cells were simultaneously screened with the commercial anti-TK1 antibody
686 ab91651.

687

688 **Fig.10.** Detection of mTK1 through flow cytometry with anti-TK1 sdAb fragments on
689 cancer cells and healthy MNC. A) NCI-H460 cells were stained with the purified phage-
690 anti-TK1 sdAb fragments, a shift in the population could be observed using both phage-
691 sdAb fragments. B-E) Expressed and purified anti-TK1-sdAb_A1 and D His-tagged and
692 VSV-G tagged were used to stain NCI-H460 (lung), HT-29 (colon), HCC1806 (Triple
693 negative breast cancer) and healthy lymphocytes. The level of mTK1 detection using
694 the anti-TK1 sdAb fragments were comparable to the levels detected by commercial
695 anti-TK1 antibody. The highest levels of mTK1 were detected on NCI-H460, following
696 HT-29 and then HCC1806. No significant binding was detected on normal MNC with the
697 anti-TK1 sdAb fragments nor with commercial anti-TK1 antibody. F) The different levels
698 of mTK1 on cancer cells and variable binding of anti-TK1 sdAb fragments. Only A1-His
699 sdAb showed consistent binding similar to commercial Ab.

700

701 After confirming the capacity of the TK1-sdAb-phages A1 and D1 to detect mTK1 on
702 cancer cells the fragments were expressed as sdAbs and used to stain different cancer
703 cell lines to test their ability to detect mTK1. The sdAbs were expressed as two different
704 versions; His-tagged and VSV-G tagged. Among the 4 sdAbs, TK1-A1-His showed the
705 most consistent binding to mTK1 on NCI-H460(~95%), HT-29(~87%) and
706 HCC1806(~53%) (Fig. 10 B-D, F). These expression levels were comparable to those
707 seen with commercial TK1 antibody 97%, 72% and 55% for NCI-H460, HT-29 and

708 HCC1806 respectively. Only in NCI-H460 cells which had the highest number of cells
709 positive for mTK1 all the fragments His and VV-G tagged showed binding (Fig. 10B).
710 D1-VSV-G fragment showed no binding in HT-29 cells and HCC1806 while A1-VSV-G
711 and A1-His showed variable levels of binding in both cell lines. However, not as
712 consistent as D1-His fragment. This may be due to differences in their tags, expression
713 levels in each cell line and possible binding to different epitopes. No significant binding
714 of the anti-TK1 sdAb fragments was found on normal lymphocytes after subtracting non-
715 specific binding of secondary antibody anti-Human IgG FITC. No significant binding of
716 the commercial anti-TK1 antibody was detected neither on normal lymphocytes (Fig
717 10E). It can be appreciated that the cancer cell lines expressed variable levels of mTK1
718 being NCI-H460 the one with the highest number of positive cells followed by HT-29
719 and HCC1806 (Fig. 10F).

720

721 **Cloning of the Anti-TK1-sdAb fragments into the pFUSE-IgG1e5 vector and**
722 **expression of recombinant antibody in CHO.K1 cells.**

723

724 Before cloning the anti-TK1-sdAb sequences into an expression vector, site directed
725 mutagenesis (SDM) was performed to change the amber stop codons present in the
726 sdAb sequences to glutamic-acid. The anti-TK1-sdAb fragments were then successfully
727 ligated into the pFUSE-IgGe5-IL2 expression vector at the NcoI and EcoRI restriction
728 sites. Restriction analysis of these constructs showed the successful insertion of the
729 sdAb genes into pFUSE-IgGe5-IL2 vector (Fig. 11A). After 72 and 96 hr of transfecting
730 CHO.K1 cells with the pFUSE-4-H-TK1_A1 and D1, and a control without sdAb

731 construct, the collected supernatant was run through a protein A column. The
732 recombinant antibodies were successfully purified from supernatant (0.4-0.26 mg/ml).
733 Western blot analysis and SDS page showed for both sdAb-Fc antibodies a ~38-40 kDa
734 band which is the expected size for the monomer of the anti-TK1-sdAb-IgG1 fusion.
735 IgG1-no sdAb construct produced alone an engineered IgG1 construct of smaller size.
736 The recombinant antibodies were all positive in Western blot to anti-human IgG
737 antibody confirming the presence of the engineered IgG1 heavy chain fused to the
738 sdAbs (Fig 11B). In addition, the recombinant antibodies showed capacity to detect
739 mTK1 on cancer cells in flow cytometry (Fig 11C). A shift in the population of NCI-H460
740 cells could be appreciated when stained with the TK1-A1-IgG1 and D1 antibodies were
741 used while no shift was detected using IgG1 fragment alone.

742
743 **Fig.11.** A) Construction of an Anti-TK1 sdAb fragment. Restriction analysis of pFUSE-
744 anti-TK1-sdAb plasmids and their respective maps. B) Expression and detection of Anti-
745 TK1-sdAb-IgG1 antibodies. As can be observed sdAb-IgG1 fusions produced higher
746 molecular weight bands compared to IgG1-no sdAb constructs. No human IgG was
747 detected in untransduced CHO.K1 cells. C) The anti-TK1-sdAb-IgG1 antibodies still
748 detecting mTK1 in NCI-H460 cells. IgG1-no sdAb did not bind to NCI-H460 cells.

749
750
751
752

753 ***Anti-TK1-sdAb antibodies elicited in vitro ADCC responses of human MNC***
754 ***against cancer cells expressing mTK1***

755
756 To test the potential use of the Anti-TK1-sdAb antibodies for the immunotargeting of
757 cancer cells that express mTK1. We co-cultured TK1 high-level expressing tumor cells
758 with human MNC, added anti-TK1-sdAb-Fc antibodies and monitored the ADCC
759 response through time. The NCI-H460 cell line was used as this cell lines previously
760 showed to express the highest levels of mTK1 on the cell surface in flow cytometry (Fig.
761 11F). An initial test using different concentrations of Anti-TK1-ssdAbs showed that the
762 cell killing was proportional to the concentration of antibody used (Fig. 12A) and it was
763 found that a concentration of 10 µg/ml of the engineered anti-TK1 antibodies was
764 necessary to cause a significant ADCC response. Cells treated with the anti-TK1-sdAb-
765 IgG1_A1 and D1 antibodies at 10 µg/ml and co-cultured with human MNCs had a
766 significant ADCC response against the cancer cells when compared to isotype
767 ($P<0.0395$) and no antibody controls ($P<0.0038$) with the (Fig. 12B) anti-TK1-sdAb-
768 IgG1_A1 after 88 hr. Although the 2-way ANOVA analysis did not show the difference
769 was significant with the anti-TK1-sdAb-IgG1_D1 antibody a reduction of more than 50%
770 of target cells was observed compared to Isotype controls. Imaging of the cells revealed
771 that after 96 hr there was a difference in the cell health and number of MNC clustering
772 targets cells. It can be visually appreciated that cells treated with anti-TK1-sdAb-IgG1
773 experienced a more severe ADCC response than thus treated with the isotype control
774 (Fig. 12B). Statistical analysis at individual time points indicates that the percentage of
775 cell killing is significantly higher at 96 hr when TK1 is targeted using the anti-TK1-sdAb-

776 IgG1_A1 ($P<0.0267$) and D1 ($P<0.0265$) compared to controls and at 72 hr ($P<0.0207$
777 and $P<0.0246$ respectively) (Fig. 12C).

778

779

780 **Fig. 12.** Anti TK1-sdAb-Fc antibodies elicit ADCC responses against NCI-H460 cells
781 expressing mTK1. A) Optimization of several antibody concentrations. The decrease in
782 GFP+ NCI-H460 cells co-cultured with MNC over time is proportional to the
783 concentration of Anti-TK1-sdAb-IgG1/ml used. B) A significant ADCC response is
784 elicited by MNCs against NCI-H460 cells when anti-TK1-sdAb-IgG1 antibodies are
785 added compared to controls. After 96hr the cell killing can visually be appreciated to be
786 more severe in the cells were treated with the anti-TK1-sdAb-IgG1 antibodies. C)
787 Percentage of cell killing calculated every 24 hr. The percentage of cell killing is
788 significantly higher after 72hr and 96hr when anti-TK1-ssdAbs are added in comparison
789 to IgG1 isotype control and effector only-no sdAb control.

790

791 **Discussion**

792 From its early beginnings' studies involving TK1 have been focused mainly on its use as
793 a tumor biomarker [42, 43]. However, new evidence has shown that TK1 may have an
794 emerging role as a tumor target for cancer therapy. Recent studies suppressing the
795 expression of TK1 in cancer cells have shown that the silencing of TK1 decreases the
796 capacity of lung adenocarcinoma, pancreatic and thyroid carcinoma cells to proliferate,
797 migrate or make mesenchymal transitions [22,23,44]. Additionally, some of the TK1
798 forms seems to be able to associate to the cell membrane of cancer cells, and event

799 that apparently restricted to malignancy. Thus, it is clear that the development of
800 therapeutics that can specifically target TK1 are necessary to explore the potential of
801 TK1 as tumor target. Monoclonal antibodies are the fastest growing biopharmaceuticals
802 in immuno-oncology [45]. Previously it has been shown that anti-TK1 monoclonal
803 antibodies could be used for the immunotargeting of TK1 in several cancer types [27].
804 Although some monoclonal antibodies against TK1 have been developed there are
805 currently no humanized versions of TK1 antibodies suitable for therapy [13, 27,46].
806 Moreover, the recent increase in the use of phage display antibody libraries have
807 proven the advantages of using sdAb fragments in the development of therapeutic
808 antibodies for cancer treatment. Single domain antibodies are characterized for their
809 smaller size while keeping all the binding properties of full-length antibodies [47]. In this
810 study anti-TK1 sdAbs were isolated from a sdAb library through phage display. This was
811 the first time that the isolation and characterization of 100% human sdAb fragments
812 specific for TK1 has been reported. This study also provides evidence that single
813 domain antibodies or nanobodies can be used to target mTK1 on cancer cells, an
814 antibody approach that has not been previously used for the targeting of TK1.
815 Furthermore, this study shows evidence that TK1 sdAbs can be incorporated in
816 engineered IgG1 antibody constructs to generate molecules for potential immuno-
817 oncology applications.

818

819 It is important to mention that the process through which we selected the antibodies
820 using TK1 produced in bacteria and TK1 produced in human cells was to make sure we
821 obtain a sufficient number of sdAbs and that the anti-TK1 sdAbs were able to bind

822 properly folded human TK1. ELISA data in this study showed that the anti-TK1 sdAbs fit
823 the receptor-ligand model and that the binding of the anti-TK1-sdAb fragments was
824 dependent of the amount of available antigen. This study also shows that the anti-TK1-
825 ssdAbs were able to be expressed without the PIII fusion while keeping their binding
826 properties previously showed in phage monoclonal ELISA. Validation with an siRNA
827 TK1 knockdown indicated that the antibody fragments developed were specific for
828 human TK1. Furthermore, the flow cytometry data showed that the nanobodies can
829 potentially be used to target cancer cells expressing TK1, particularly mTK1. This early
830 evidence indicates that anti-TK1-ssdAbs could be used for the development of
831 experimental TK1-based therapeutics such as anti-TK1-sdAb fragments that could be
832 conjugated with toxins or gold nanoparticles for anticancer photothermal therapy [48,
833 49]. Moreover, the anti-TK1-sdAb fragments could also be used for the development of
834 immuno-oncology therapeutics such as engineered antibodies or chimeric antigen
835 receptors [50].

836
837 As this study has shown, anti-TK1-sdAb-IgG1 antibodies are capable of targeting mTK1
838 on cancer cells and elicit an ADCC response of human MNC against TK1 high-level
839 expressing cancer cells building up on previous findings. Contrary to previous anti-TK1
840 antibodies generated through conventional hybridoma technology, these engineered
841 antibodies are completely human, are significantly smaller than full length antibodies
842 and have an engineered IgG1 to enhance the ADCC response. Thus, they can have
843 better tumor penetration than conventional antibodies, and can be used to better
844 engage the immune system with tumor cells. Although it remains unclear why TK1 is

845 localized to the cell surface of multiple cancer cell lines, the flow cytometry data and
846 ADCC results described here suggest that it could be feasible to harness the immune
847 system against tumor cells expressing mTK1. It is not the first time that a protein
848 thought to be limited to the interior of the cell has been reported to be on the cell
849 surface. Examples can be found in the HSP70 family of proteins. Although HSP70
850 proteins were thought to be limited to function only inside cells, it is well documented
851 that they are secreted and localized on the cell membrane of cancer cells [51-52]
852 Recent studies have shown that TK1 is present in exosomes [26]. Like HSP70 proteins
853 a possible explanation could be that it is transitorily localized on the cell membrane as
854 exosomes exit the cell fusing to the cell membrane, and through non-conventional
855 protein-protein interactions. Moreover, it is also important to point out that other
856 nucleotide salvage pathway enzymes have been reported to be localized on the cell
857 membrane such as hypoxanthine-phosphoribosyl transferase (HPRT). Targeting of this
858 enzyme with monoclonal antibodies has also been recently reported [53].

859

860 **Conclusion**

861 This study reports the isolation and evaluation of human single domain antibodies
862 against TK1 for the targeting of the tumor proliferation biomarker TK1 in lung, colon and
863 breast cancer cells. The antibody fragments have potential as diagnostic and
864 therapeutic agents. Although additional *in vivo* studies are required to confirm their
865 efficacy. The antibody fragments can be successfully incorporated into IgG1 Fc
866 constructs for the production of completely human engineered antibodies able to elicit
867 significant ADCC responses from human MNC against cancer cells expressing mTK1.

868 The antibody fragments potentially can be used in other therapies such as chimeric
869 antigen receptors (CAR) for T cells or other recombinant antibody constructs. The use
870 of TK1 as a tumor target will enable the testing of experimental TK1-based therapeutics.

871

872 **Declarations**

873

874 ***Ethics approval and consent to participate***

875

876 Isolation of human MNCs and serum from blood was obtained under approval of
877 the Brigham Young University Institutional Review Board number 1734.

878

879 ***Consent for publication***

880

881 Personal information details from individual that donated blood were not included
882 in this manuscript

883

884 ***Availability of data and materials***

885

886 All the relevant information is contained within this manuscript. Additional files
887 regarding this study will be available from the authors upon a reasonable request basis.

888

889

890

891 ***Competing interests***

892

893 The author declares no competing interests associated to this study

894

895 ***Funding***

896 Funding for this research was obtained partially from Thunder Biotech. Funding
897 was also provided through a cancer fellowship from the BYU's Simmons Center for
898 Cancer Research and the department of Microbiology and Molecular Biology at Brigham
899 Young University. Finally, this research was also partially sponsored with a scholarship
900 from the Mexican Council of Science and Technology (CONACyT)

901

902 ***Authors' contributions***

903 EJV and KLO conceived the original scientific questions and experimental design
904 of this research. EJV was the major contributor in the collection and analysis of the data
905 of this manuscript. JDC, TBH, TOM, DMB, JRS and KRS assisted in the selection and
906 evaluation of single domain antibodies, Western blot, ELISA, purification of antibodies
907 and cell culture. EJV, KLO, RAR and SKW Contributed to the interpretation of the data
908 and writing of this manuscript.

909

910 ***Acknowledgments***

911 We acknowledge the valuable contributions of Naomi Raper, Kelsey Bingham,
912 and Zachary Ewel for their technical support during the early stages of this research.

913

914 **References**

915

916 1. Buj R and Aird MK. Deoxyribonucleotide Triphosphate Metabolism in Cancer and
917 Metabolic Disease. *Front endocrinol.* 2018;9:177. doi: 10.3389/fendo.2018.00177

918

919 2. Traut TW. Physiological concentrations of purines and pyrimidines. *Mol cell*
920 *biochem.* 1994;140(1);1-22. <https://doi.org/10.1007/BF00928361>

921

922 3. Villa E, Ali SE, Sahu U, Sahra IB. Cancer cells tune the signaling pathways to
923 empower de novo synthesis of nucleotides. *Cancers.* 2019;11(5):688.
924 doi: 10.3390/cancers11050688

925

926 4. Loffler M, Fairbanks LD, Zameitat E, Marinaki AM, Simmonds HA. Pyrimidine
927 pathways in health and disease. *TRENDS mol med.* 2005;11:9.
928 doi:10.1016/j.molmed.2005.07.003.

929

930 5. Somyajit K, Gupta R, Sedlackova H, Neelsen KJ, Ochs F, Rask MB, Choudhary
931 C, Lukas J. Redox-sensitive alteration of replisome architecture safeguards
932 genome integrity. *Science.* 2017;358:797-802

933

934 6. Munch-Petersen B, Cloos L, Jensen HK and Tyrsted G. Human Thymidine
935 Kinase 1 regulation in normal and malignant cells. *Advan. Enzyme Regul.*
936 1995;35:68-69

- 937
- 938 7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*.
- 939 2011;144:646-674. doi: 10.1016/j.cell.2011.02.013.
- 940
- 941 8. Birring MS, Perozzo R, Kut E, Stillhart C, Surber W, Scapozza L, Folkers G.
- 942 High-level expression and purification of human thymidine kinase 1 : Quaternary
- 943 structure , stability , and kinetics. *Protein expression purify*. 2006;47:506-515.
- 944 doi:10.1016/j.pep.2006.01.001
- 945
- 946 9. Zhou J, He E, Skog S. The proliferation marker thymidine kinase 1 in clinical use.
- 947 *Mol Clin Oncol*. 2013;1:18-28. doi: 10.3892/mco.2012.19
- 948
- 949 10. Ke, P. Y., & Chang, Z. F. (2004). Mitotic degradation of human thymidine kinase
- 950 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated
- 951 pathway. *Molecular and cellular biology*, 24(2), 514–526.
- 952 <https://doi.org/10.1128/mcb.24.2.514-526.2004>
- 953
- 954 11. Kauffman MG, Kelly TJ. Cell cycle regulation of thymidine kinase: residues near
- 955 the carboxyl terminus are essential for the specific degradation of the enzyme at
- 956 mitosis. *Mol Cell Biol*. 1991 11:2538–2546. doi: 10.1128/mcb.11.5.2538

957

958 12. Gatt ME, Goldschmidt N, Kalichman I, Friedman M, Arronson AC, Barak V.
959 Thymidine Kinase Levels Correlate with Prognosis in Aggressive Lymphoma and
960 Can Discriminate Patients with a Clinical Suspicion of Indolent to Aggressive
961 Transformation. *Anticancer Res.* 2015;35:3019-3026.

962

963 13. Jagarlamudi KK, Aronsson AC, Pilko G, Zupan M, Kumer K, Fabjan T. A clinical
964 evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates
965 high sensitivity and specificity in all stages of disease. *Tumor Biology.*
966 2016;37:11937–11945. doi: 10.1007/s13277-016-5024-z

967

968 14. Wang Y, Jiang X, Wang S, Yu H, Zhang T, Xu S, Li W, He E and Skog S.
969 Serological TK1 predict pre-cancer in a routine health screening of 56, 178
970 people. *Cancer Biomark.* 2018;22(2):237-247. DOI: 10.3233/cbm-170846

971

972 15. Alegre MM, Weyant MJ, Bennett DT, Yu JA, Ramsden MK, Elnaggar A, Robison
973 RA, O'Neill KL. Serum detection of thymidine kinase 1 as a means of early
974 detection of lung cancer. *Anticancer Res.* 2014;34(5), 2145–51.

975

976 16. Alegre, MM, Robison, RA, O'Neill K L. Thymidine Kinase 1 Upregulation is an
977 Early Event in Breast Tumor Formation. *J. of Oncol.* 2012;2012:1–5.

978

- 979 17. Chen ZH, Huang SQ, Wang Y, Yang AZ, Wen J, Xu XH, Chen Y, Chen QB,
980 Wang YH, He E, Zhou J, Skog S. Serological thymidine kinase 1 is a biomarker
981 for early detection of tumours-a health screening study on 35,365 people, using a
982 sensitive chemiluminescent dot blot assay. *Sensors*. 2011;11(12):11064-80. doi:
983 10.3390/s111211064
984
- 985 18. Chen Y, Ying M, Chen YS, Hu M, Lin Y, Chen D, Li X, Zhang M, Yun X, Zhou J,
986 He E, Skog S. Serum thymidine kinase 1 correlates to clinical stages and clinical
987 reactions and monitors the outcome of therapy of 1,247 cancer patients in routine
988 clinical settings. *Int. J. of Clin. Oncol*. 2010;15(4), 359–368.
989
- 990 19. Hallek M, Wanders L, Strohmeyer S, Emmerich B. Thymidine Kinase 1: a tumor
991 marker with prognostic value for non-Hodgkin's lymphoma and a broad range of
992 potential clinical applications. *Ann. of hematology*. 1992;65(1):1-5.
993
- 994 20. He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE, Skog S.
995 Thymidine Kinase1 in serum predicts increased risk of distant or loco-regional
996 recurrence following surgery in patients with early breast cancer. *Anticancer Res*.
997 2006;26:4753-4760.
998
- 999 21. Jagarlamud KK, Shaw M. Thymidine kinase 1 as a tumor biomarker: Technical
1000 advances offer new potential to an old biomarker. *Biomark. in Med*.
1001 2018;12:1035–1048. doi: 10.2217/bmm-2018-0157

- 1002
- 1003 22. Malvi P, Janostiak R, Nagarajan A, Cai G, Wajapeyee N (2019) Loss of
- 1004 thymidine kinase 1 inhibits lung cancer growth and metastatic attributes by
- 1005 reducing GDF15 expression. PLoS Genet 15(10): e1008439.
- 1006 <https://doi.org/10.1371/journal.pgen.1008439>
- 1007
- 1008 23. Zhu X, Shi C, Peng Y, Yin L, Tu M, Chen Q, Hou C, Li Q and Miao Y. Thymidine
- 1009 Kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-
- 1010 TK1-P21 axis. Cell proliferat. 2018;51:e12428.
- 1011
- 1012 24. Weagel EG, Meng W, Townsend MH, Velazquez EJ, Brog RA, Boyer MW,
- 1013 Weber SK, Robison RA, O'Neill KL. Biomarker analysis and clinical relevance of
- 1014 TK1 on the cell membrane of Burkitt's lymphoma and acute lymphoblastic
- 1015 leukemia. OncoTargets and Therapy. 2017;10:4355–4367.
- 1016
- 1017 25. Weagel EG, Burrup W, Kovtun R, Velazquez EJ, Felsted AM., Townsend MH,
- 1018 Zachary EE., Suh E, Piccolo SR, Weber SK, Robison RA, O'Neill KL. Membrane
- 1019 expression of thymidine kinase 1 and potential clinical relevance in lung, breast,
- 1020 and colorectal malignancies. Cancer Cell Int. 2018;18:135.
- 1021
- 1022 26. Shojai TM. The mechanism of TK1 secretion in cancer cells (unpublished thesis).
- 1023 Swedish University of Agricultural Sciences, Upssala, Sweden.

- 1024
- 1025 27. Velazquez EJ, Brindley TD, Shrestha G, Bitter EE, Cress JD, Townsend MH,
1026 Berges BK, Robison RA, Weber KS, O'Neill KL. Novel monoclonal antibodies
1027 against thymidine kinase 1 and their potential use for the immunotargeting of
1028 lung, breast and colon cancer cells. 2020;20:127. [https://doi.org/10.1186/s12935-](https://doi.org/10.1186/s12935-020-01198-8)
1029 [020-01198-8](https://doi.org/10.1186/s12935-020-01198-8)
- 1030
- 1031 28. Parakh S., King D., Gan H.K., Scott A.M. (2020) Current Development of
1032 Monoclonal Antibodies in Cancer Therapy. In: Theobald M. (eds) Current
1033 Immunotherapeutic Strategies in Cancer. Recent Results in Cancer Research,
1034 vol 214. Springer, Cham. https://doi.org/10.1007/978-3-030-23765-3_1
- 1035
- 1036 29. Lu, R., Hwang, Y., Liu, I. et al. Development of therapeutic antibodies for the
1037 treatment of diseases. J Biomed Sci **27**, 1 (2020).
1038 <https://doi.org/10.1186/s12929-019-0592->
1039
- 1040 30. Manis JP. Overview of therapeutic antibodies. 2020. Accessed [2020 May 3]
1041 [https://www.uptodate.com/contents/overview-of-therapeutic-monoclonal-](https://www.uptodate.com/contents/overview-of-therapeutic-monoclonal-antibodies#H26)
1042 [antibodies#H26](https://www.uptodate.com/contents/overview-of-therapeutic-monoclonal-antibodies#H26)
- 1043
- 1044 31. Almagro JC, Pedraza-Escalona M, Arrieta HI, Perez-Tapia SM. Phage display
1045 libraries for antibody therapeutic discovery and development. Antibodies.
1046 2019;8:44. doi:10.3390/antib8030044

1047

1048 32. Zhao A, Tohidkia MR, Siegel DL, Coukos G, Omidi Y. Phage antibody display
1049 libraries: a powerful antibody discovery platform for immunotherapy. *Crit. Rev.*
1050 *Biotechnol.* 2016;36(2):276-289. doi: 10.3109/07388551.2014.958978

1051

1052 33. Barderas, R., Benito-Peña, E. The 2018 Nobel Prize in Chemistry: phage display
1053 of peptides and antibodies. *Anal Bioanal Chem* **411**, 2475–2479 (2019).
1054 <https://doi.org/10.1007/s00216-019-01714-4>

1055

1056 34. Frenzel A, Schirmann T, Hust M. Phage display-derived human antibodies in
1057 clinical development and therapy. *MABS.* 2016;8(7):1177-1194.
1058 <http://dx.doi.org/10.1080/19420862.2016.1212149>

1059

1060 35. Marintcheva B. (2018) Phage display. *Harnessing the power of viruses.* (pp 133-
1061 160). <https://doi.org/10.1016/B978-0-12-810514-6.00005-2>

1062

1063 36. Lee, C. M., Iorno, N., Sierro, F., & Christ, D. (2007). Selection of human antibody
1064 fragments by phage display. *Nature protocols*, 2(11), 3001.

1065

1066 37. Genius Prime 2019.0.3. <https://www.geneious.com>.


1067

- 1068 38. Humphrey, W., Dalke, A. and Schulten, K., "VMD - Visual Molecular Dynamics",
1069 J. Molec. Graphics, 1996, vol. 14, pp. 33-38.
1070
- 1071 39. G.C.P van Zundert, J.P.G.L.M. Rodrigues, M. Trellet, C. Schmitz, P.L. Kastiris,
1072 E. Karaca, A.S.J. Melquiond, M. van Dijk, S.J. de Vries and A.M.J.J. Bonvin
1073 (2016). "The HADDOCK2.2 webserver: User-friendly integrative modeling of
1074 biomolecular complexes." J. Mol. Biol., **428**, 720-725 (2015).
1075
- 1076 40. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition.
1077 New York: Garland Science; 2002. The Shape and Structure of
1078 Proteins. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK26830/>
1079
- 1080 41. Welin M, Kosinska U, Mikkelsen N, Carnrot C, Zhu C, Wang L, Eriksson S,
1081 Munch-Petersen B, and Eklund H. Structures of thymidine kinase 1 of human
1082 and mycoplasmic origin. PNAS. 2004;101:17970-17975
1083
- 1084 42. O'Neill KL, Buckwalter M, Murray BK. "Thymidine kinase: diagnostic and
1085 prognostic potential". *Expert Rev. Mol. Diagn.* 1 (4): 428–
1086 33. doi:10.1586/14737159.1.4.428
1087
- 1088 43. Ondrej Topolcan & Lubos Holubec Jr. The role of thymidine kinase in cancer
1089 diseases, *Expert Opinion on Medical Diagnostics*, 2:2, 129-
1090 141, DOI: 10.1517/17530059.2.2.129

- 1091
- 1092 44. Liu C, Wang J, Zhao L, He H, Zhao P, Peng Z, Liu F, Chen J, Wu W, Wang G
1093 and Dong F. Knockdown of Thymidine Kinase 1 Suppresses Cell Proliferation,
1094 Invasion, Migration, and Epithelial–Mesenchymal Transition in Thyroid
1095 Carcinoma Cells. *Front. Oncol.* 9:1475. doi: 10.3389/fonc.2019.01475
1096
- 1097 45. To cite this article: Philippe Valadon, Sonia M. Pérez-Tapia, Renae S. Nelson,
1098 Omar U. Guzmán- Bringas, Hugo I. Arrieta-Oliva, Keyla M. Gómez-Castellano,
1099 Mary Ann Pohl & Juan C. Almagro (2019) ALTHEA Gold Libraries™: antibody
1100 libraries for therapeutic antibody discovery, *mAbs*, 11:3, 516-531, DOI:
1101 10.1080/19420862.2019.1571879
1102
- 1103 46. US patent. US 2010/0173329 A1
1104
- 1105 47. Schrankel CS, Gökirmak T, Lee CW, Chang G, Hamdoun A. *Methods in cell*
1106 *biology*. Chapter 14-generation, expression and utilization of single-domain
1107 antibodies for *in vivo* protein localization and manipulation in sea urchin embryos.
1108 Elsevier 2019;151:353-376.
1109
- 1110 48. Van de Broek B, Devoogdt N, D'Hollander A, et al. Specific cell targeting with
1111 nanobody conjugated branched gold nanoparticles for photothermal
1112 therapy. *ACS Nano*. 2011;5(6):4319-4328. doi:10.1021/nn1023363
1113



- 1114 49. Yu, Y., Li, J., Zhu, X., Tang, X., Bao, Y., Sun, X., Huang, Y., Tian, F., Liu, X., &
1115 Yang, L. (2017). Humanized CD7 nanobody-based immunotoxins exhibit
1116 promising anti-T-cell acute lymphoblastic leukemia potential. *International journal*
1117 *of nanomedicine*, 12, 1969–1983. <https://doi.org/10.2147/IJN.S127575>
1118
- 1119 50. Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M (August 2017). "Therapeutically
1120 targeting glypican-2 via single-domain antibody-based chimeric antigen receptors
1121 and immunotoxins in neuroblastoma". *Proceedings of the National Academy of*
1122 *Sciences of the United States of America*. 114 (32): E6623–
1123 E6631. doi:10.1073/pnas.1706055114
1124
- 1125 51. Vega, V. L., Rodríguez-Silva, M., Frey, T., Gehrmann, M., Diaz, J. C., Steinem,
1126 C., Multhoff, G., Arispe, N., & De Maio, A. (2008). Hsp70 translocates into the
1127 plasma membrane after stress and is released into the extracellular environment
1128 in a membrane-associated form that activates macrophages. *Journal of*
1129 *immunology (Baltimore, Md. : 1950)*, 180(6), 4299–4307.
1130 <https://doi.org/10.4049/jimmunol.180.6.4299>
1131
- 1132 52. De Maio A. (2014). Extracellular Hsp70: export and function. *Current protein &*
1133 *peptide science*, 15(3), 225–231.
1134 <https://doi.org/10.2174/1389203715666140331113057>
1135

1136 53. Townsend, M. H., Bennion, K. B., Bitter, E. E., Felsted, A. M., Robison, R. A., &
1137 O'Neill, K. L. (2021). Overexpression and surface localization of HPRT in
1138 prostate cancer provides a potential target for cancer specific antibody mediated
1139 cellular cytotoxicity. *Experimental cell research*, 403(1), 112567. Advance online
1140 publication. <https://doi.org/10.1016/j.yexcr.2021.112567>
1141

A**B**


Eluted phages per round of selection

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.04.21256554>; this version posted May 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](#).

**C**

A

New clones binding full-length TK1




- E-TK1 1st
- E-TK1 2nd
- E-TK1 3rd
- H-TK1 4th
- H-TK1 5th

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.04.21251554>; this version posted May 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

B



Enrichment of TK1 binders through rounds of selection



- 1st biopan
- 2nd biopan
- 3rd biopan
- 4th biopan
- 5th biopan


C

Detection of phage-antibodies with anti-VSV-G antibody

**D**

A





Confirmation of positive clones



B


3-E-TK1_3E	3-E-TK1_3E	4-H-TK1_A1	4-H-TK1_A1	4-H-TK1_F11	4-H-TK1_F11	Anti-M13	Blank
3-E-TK1_5F	3-E-TK1_5F	4-H-TK1_D1	4-H-TK1_D1	3-E-TK1_A7	2-E-TK1_7D	Anti-M13	Blank
3-E-TK1_6D	3-E-TK1_6D	4-H-TK1_G1	4-H-TK1_G1	3-E-TK1_A8	2-E-TK1_8E	Anti-M13	Blank
3-E-TK1_7C	3-E-TK1_7C	4-H-TK1_A4	4-H-TK1_A4	2-E-TK1_C1	2-E-TK1_C1		
3-E-TK1_8H	3-E-TK1_8H	4-H-TK1_G4	4-H-TK1_G4	2-E-TK1_C2	2-E-TK1_C2		
2-E-TK1_3G	2-E-TK1_3G	4-H-TK1_C9	4-H-TK1_C9	2-E-TK1_C4	2-E-TK1_C4	+	
2-E-TK1_4B	2-E-TK1_4B	4-H-TK1_H6	4-H-TK1_H6	2-E-TK1_D3	2-E-TK1_D3	+	
2-E-TK1_7A	2-E-TK1_7A	4-H-TK1_B11	4-H-TK1_B11	2-E-TK1_D6	2-E-TK1_D6	+	






A**2-E-TK1 clones****3-E-TK1 clones****4-H-TK1 clones****B**

A

Signal at
23ng/ml of H-TK1


**B**

Binding of Anti-TK1-dAb phages to H-TK1




**C****D**





A





3-E-TK1_3E
3-E-TK1_6D
4-H-TK1_A1
4-H-TK1_D1
4-H-TK1_C9
3-E-TK1_A7
3-E-TK1_H6

**B**


PET-4-H-TK1_A1
PET-4-H-TK1_D1
PET-4-H-TK1_C9
PET-4-H-TK1_F11

**C****D**






A Sensitivity of clones using H-TK1




medRxiv preprint doi: <https://doi.org/10.1101/2021.05.04.21256554>; this version posted May 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).




B



C




D




A

Detection of mTK1 using purified anti-TK1 dAb phages


**B**

Detection of mTK1 using recombinant anti TK1-dAbs on NCI-H460 (Non-small cell lung carcinoma cells)




C

Detection of mTK1 using recombinant anti TK1-dAbs on HT-29 (colon adeno carcinoma cells)


**D**

Detection of mTK1 using recombinant anti TK1-dAbs on HCC1806 (Triple negative breast cancer cells)







E

Detection of mTK1 using recombinant anti TK1-dAbs on Healthy PBMNCs

**F**


Detection of mTK1 expression levels on cancer cells and normal MNC using anti-TK1 dAbs






A


TK1_A1-IgG1 titration curves



TK1_D1-IgG1 titration curves

**B**


ADCC response from human MNC against H460 mTK1+ cells

**C**

IgG1

OriTK1-A1-IgG1

OriTK1-D1-IgG1

**D**

Cell killing

